Lv1
20 积分 2025-05-08 加入
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
23天前
已完结
Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001, -010, and -024
28天前
已完结
130O Real-world prevalence of PD-L1 expression in locally advanced or metastatic non-small cell lung cancer (NSCLC): The global, multicentre EXPRESS study
28天前
已完结
Global Incidence, Mortality, Risk Factors and Trends of Melanoma: A Systematic Analysis of Registries
2个月前
已完结
Cancer burden and control in China: landscape, trends and challenges
2个月前
已完结
Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment
4个月前
已完结
Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial
4个月前
已完结
Epidemiology and Retrospective Analysis in Extrapulmonary Neuroendocrine Carcinoma
4个月前
已完结
The global burden of lung cancer: current status and future trends
5个月前
已完结
Efficacy of PD-1/PDL-1 inhibitors for ovarian cancer: a systematic review and network meta-analysis
5个月前
已完结
皖公网安备34019202002308
